Keefe, Bruyette & Woods Reiterates “Outperform” Rating for Hyperion Therapeutics (HPTX)
Hyperion Therapeutics (NASDAQ:HPTX)‘s stock had its “outperform” rating reiterated by equities researchers at Keefe, Bruyette & Woods in a research report issued on Friday. They currently have a $37.00 price objective on the stock, down from their previous price objective of $39.00. Keefe, Bruyette & Woods’ price target suggests a potential upside of 62.35% from the company’s current price.
Shares of Hyperion Therapeutics (NASDAQ:HPTX) opened at 22.79 on Friday. Hyperion Therapeutics has a 52-week low of $18.97 and a 52-week high of $32.98. The stock’s 50-day moving average is $24.40 and its 200-day moving average is $26.17. The company has a market cap of $461.8 million and a price-to-earnings ratio of 17.77.
Hyperion Therapeutics (NASDAQ:HPTX) last released its earnings data on Thursday, August 7th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.84. The company had revenue of $37.10 million for the quarter, compared to the consensus estimate of $22.00 million. During the same quarter in the previous year, the company posted $1.17 earnings per share. The company’s revenue for the quarter was up 408.2% on a year-over-year basis. On average, analysts predict that Hyperion Therapeutics will post $-0.23 earnings per share for the current fiscal year.
Hyperion Therapeutics, Inc (NASDAQ:HPTX)is a development-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.